Bio-Rad Laboratories, Inc. (NYSE:BIO.B – Get Free Report) shares hit a new 52-week high on Monday . The stock traded as high as $337.00 and last traded at $337.00, with a volume of 63 shares traded. The stock had previously closed at $298.50.
Bio-Rad Laboratories Stock Performance
The firm has a market cap of $9.02 billion, a price-to-earnings ratio of 55.52 and a beta of 0.93. The company has a fifty day moving average price of $304.67 and a 200-day moving average price of $288.38. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.
In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.
Recommended Stories
- Five stocks we like better than Bio-Rad Laboratories
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
